FDA approved biosimilars used to aide the treatment of cancer, such as trastuzumab (146 kDa, Figure ) and bevacizumab (149 kDa, Figure ) have been helped by increased scale-ups , improved flow rates and concentrations in bioprocesses, and also now have significant commercial market shares . The Introduction section in this work was summarized by the manuscript author, which included 5 Papers on mAb production improvements, 5 papers on mAb continuous production improvements, and 6 papers on mAb production AI improvements. The time required for the human researcher to read each paper abstract and write a brief summary was effectively 110x slower than the slowest o1-preview model times when adjusting for same number of words.